Standard BioTools Inc (LAB)

Industry Medical Devices


This stock can be held in an Investment ISA and an Investment Account
Sell

$0.95

Buy

$0.9848

arrow-down$-0.0149 (-1.49%)

Prices updated at 16 May 2026, 00:40 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies.
Sector
Healthcare
Industry
Medical Devices
Chairman
Mr. Thomas Carey
CEO
Dr. Michael Egholm, PhD
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
389
Head office
50 Milk Street
Boston
United States
02109
mobile
+1 650 266-6000
letter
agnes.lee@fluidigm.com

Key personnel

Salary
Mr. Fenel M. Eloi
Independent Director
0.07m
Ms. Kathy L. Hibbs, J.D.
Independent Director
0.07m
Dr. Michael Egholm, PhD
President, Chief Executive Officer and Director
0.68m
Mr. Troy M. Cox, M.B.A.
Independent Director
0.07m
Mr. Eli D. Casdin, M.B.A.
Independent Director
0.06m
Dr. Franklin R. Witney, PhD
Independent Director
0.08m
Mr. Sean Mackay
Chief Business Officer
0.47m
Mr. Hanjoon Alex Kim
Chief Financial Officer and Principal Accounting Officer
0.50m
Mr. Thomas Carey
Chairman of the Board
0.11m

Top 5 shareholders

No. of shares
Casdin Capital, LLC88,783,856
Viking Global Investors LP58,651,170
BlackRock Inc25,515,933
Mak Capital One LLC19,288,158
Vanguard Group Inc17,297,599

Director dealings

Action
20 Nov 2025-
20 Nov 2025-
20 Nov 2025-
20 Aug 2025-
20 Aug 2025-
20 Aug 2025-
01 Aug 2025-
01 Aug 2025-
20 Jun 2025-
20 Jun 2025-
20 Jun 2025-
20 Jun 2025-
20 Jun 2025-
20 Jun 2025-
20 Jun 2025-
20 Jun 2025-
28 May 2025-
28 May 2025-
28 May 2025-
23 May 2025-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.